Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Hyaluronidase/pertuzumab/trastuzumab - Roche

Next Previous
Drug Profile

Hyaluronidase/pertuzumab/trastuzumab - Roche

Alternative Names: Herceptin/perjeta; Perjeta/herceptin; Pertuzumab FDC SC; Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf; Pertuzumab/trastuzumab; PH FDC SC; Phesgo; Phesgo OBI; RG 6264; Trastuzumab/pertuzumab

Latest Information Update: 26 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Roche
  • Developer Chugai Pharmaceutical; International Breast Cancer Study Group; Medica Scientia Innovation Research; Merck & Co; Roche; Seagen
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Dimerisation inhibitors; Hyaluronidase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed HER2 positive breast cancer
  • Registered Colorectal cancer
  • Phase II Solid tumours

Most Recent Events

  • 27 Feb 2024 Genentech completes a phase II trial in Solid tumours (Inoperable/Unresectable, Late-stage disease, Metastatic disease) in USA (PO) (NCT04632992)
  • 15 Feb 2024 Discontinued - Phase-I/II for HER2-positive-breast-cancer (Combination therapy, Metastatic disease, Second-line therapy or greater) in Austria, Belgium, France, Italy, Australia (Parenteral) (Roche pipeline, February 2024)
  • 14 Dec 2023 Seagen has been acquired by Pfizer
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top